Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma

被引：9

作者：

Martinez-Trufero, Javier ^{[1
]}

Alfaro, Jorge ^{[2
]}

Felipo, Francesc ^{[2
]}

Alvarez, Maria ^{[1
]}

Madani, Julia ^{[1
]}

Cebollero, Ana ^{[1
]}

机构：

[1] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza 50009, Spain

[2] Hosp Univ Miguel Servet, Dept Pathol, Zaragoza 50009, Spain

来源：

ANTI-CANCER DRUGS | 2010年 / 21卷 / 08期

关键词：

hemangiopericytoma; rare tumor; solitary fibrous tumor; trabectedin; SOFT-TISSUE SARCOMA; CENTRAL-NERVOUS-SYSTEM; MALIGNANT HEMANGIOPERICYTOMA; PHASE-II; FIBROUS TUMOR; ECTEINASCIDIN-743; CHEMOTHERAPY; RADIOTHERAPY; EXPERIENCE; SUNITINIB;

D O I：

10.1097/CAD.0b013e32833d19f0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Meningeal hemangiopericytoma is an uncommon and aggressive malignancy that, in contrast to meningiomas, shows a high propensity for local recurrence and the development of late extraneural metastases. The results of chemotherapy in advanced hemangiopericytoma have been disappointing, and they have been particularly poor in cases located in the meninges. We report a case of a heavily pretreated metastatic meningeal hemangiopericytoma in which fourth-line chemotherapy with trabectedin, a marine-derived antineoplastic agent effective in treating advanced soft tissue sarcomas, resulted in clinical benefit. Anti-Cancer Drugs 21: 795-798 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

引用

页码：795 / 798

页数：4

共 50 条

[1] Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases
Zanardi, Elisa
Maruzzo, Marco
Montesco, Maria C.
Roma, Anna
Rastrelli, Marco
Basso, Umberto
ANTI-CANCER DRUGS, 2014, 25 (10) : 1227 - 1230
[2] Trabectedin: Novel Insights in the Treatment of Advanced Sarcoma
Lopez, Jay Patrick
Gajdos, Csaba
Elias, Anthony
CURRENT ONCOLOGY REPORTS, 2014, 16 (06)
[3] Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: A case report and literature review
Corrado, Giacomo
Salutari, Vanda
Fuoco, Gilda
Lucidi, Alessandro
Ferrandina, Gabriella
GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 416 - 417
[4] Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma
Blay, Jean Yves
Casali, Paolo
Nieto, Antonio
Tanovic, Adnan
Le Cesne, Axel
FUTURE ONCOLOGY, 2014, 10 (01) : 59 - 68
[5] Prolonged response to treatment with trabectedin in a patent with a diagnosis of advanced synovial sarcoma
Kosela, Hanna
Wiater, Katarzyna
Switaj, Tomasz
Rutkowski, Piotr
ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (03): : 119 - 122
[6] Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma
Doherty, Gary J.
Davidson, Dochka
Wong, Han H.
Hatcher, Helen M.
ANTI-CANCER DRUGS, 2019, 30 (01) : 110 - 115
[7] A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma
Le Cesne, Axel
Martin-Broto, Javier
Grignani, Giovanni
FUTURE ONCOLOGY, 2022, 18 (30S) : 5 - 11
[8] A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin
Galera, Mar
Alvarez, Rosa
Arregui, Marta
Paniagua, Miguel
Alvarez, Ana
Gonzalez Crisostomo, Raphael Angelo
Diazgranados, Adriana
Gutierrez, Natalia
Calles, Antonio
Agra, Carolina
CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1542 - 1550
[9] Hemangiopericytoma of the skull base: A long-term complete response with trimodality treatment
Bolukbas, Meltem K.
Akovali, Emine S.
Musri, Fatma Y.
Demirtas, Rabia
INDIAN JOURNAL OF CANCER, 2024, 61 (02) : 337 - 341
[10] Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma
Baldi, Giacomo G.
Di Donato, Samantha
Fargnoli, Rossana
Dona, Manjola
Bertulli, Rossella
Parisi, Elisabetta
Fantini, Lorenzo
Sbaraglia, Marta
Panella, Mauro
ANTI-CANCER DRUGS, 2016, 27 (09) : 908 - 913

← 1 2 3 4 5 →